Failure of high dose steroids in severe COVID-19 treatment despite prior success of low dose dexamethasone.
-
Oxford’s Recovery Trial showed no benefit of higher dose corticosteroids in non-ventilated COVID-19 patients. • 0:02
-
Question raised on why Oxford did not continue to research optimal dose after initial success. • 1:56
-
Initial study in June 2020 demonstrated significant benefit of low dose dexamethasone in reducing COVID-19 deaths. • 2:08
-
Recent study found no benefit and excess of pneumonia with higher dose steroids compared to usual care. • 3:08
-
Significant impact of original low dose dexamethasone study in saving lives globally during COVID-19 pandemic. • 3:55
Investigating the unexpected failure of high dose steroids in severe COVID-19 treatment.
-
Oxford credited for changing global standards with research • 4:34
-
Higher dose steroids associated with higher risk of ventilation in severe COVID-19 patients • 7:02
-
Significant differences in patient characteristics and study location between cohorts • 8:09
-
50% of patients had received a COVID-19 vaccine, potentially impacting study results • 9:04
Ineffectiveness of high-dose steroids in severe COVID-19 and potential conflicts of interest in treatment research.
-
High-dose steroids may not be as effective for Omicron variant as for earlier variants. • 9:32
-
Research suggests Omicron concentrates in central lungs, affecting steroid effectiveness. • 10:50
-
Concerns raised about conflicts of interest in treatment research outcomes. • 11:16
-
Importance of optimizing treatment options for COVID-19 to save lives. • 12:04